Lebanon Pharmaceuticals and Healthcare Report Q2 2010

Executive Summary ..................................................5
SWOT Analysis..........................................................6
Lebanon Pharmaceuticals And Healthcare Industry SWOT ........................................... 6
Political SWOT........................ 7
Economic SWOT....................... 8
Business Environment SWOT.......................................................................................... 9
Business Environment Ratings ..............................10
Table: Middle East and Africa – Regional Pharmaceuticals Business Environment Ratings For Q210.............................................................. 10
Limits To Potential Returns .......................................................................................... 11
Risks To Realisation Of Returns ................................................................................... 11
Lebanon – Market Summary ...................................13
Regulatory Regime..................................................14
Public Sector Procurement ........................................................................................... 14
Intellectual Property Regime ........................................................................................ 15
IP Shortcomings...................... 16
Parallel Imports...................... 17
Counterfeit Drugs ................... 17
Free Trade Agreements................................................................................................. 19
Pricing and Reimbursement Issues ............................................................................... 20
Industry Developments...........................................22
Epidemiology.......................... 22
HIV/AIDS Infections ............... 24
Healthcare Sector ................... 24
Hospital Sector ....................... 25
Healthcare Insurance ................................................................................................... 26
Healthcare Sector Reforms ........................................................................................... 27
Retail Pharmacy Sector ................................................................................................ 28
Regional Developments ................................................................................................ 28
Clinical Trials......................... 29
Medical Devices...................... 29
Industry Forecast Scenario .....................................31
Overall Market Forecast............................................................................................... 31
Key Growth Factors – Industry..................................................................................... 32
Key Growth Factors – Macroeconomic ........................................................................ 33
Table: Lebanon – Economic Activity ............................................................................ 35
Prescription Drug Market Forecast.............................................................................. 36
Patented Drug Market Forecast ................................................................................... 37
Generic Drug Market Forecast..................................................................................... 38
OTC Medicine Market Forecast ................................................................................... 41
Pharmaceutical Trade Forecast ................................................................................... 42
Other Healthcare Data Forecasts................................................................................. 43
Key Risks to Forecasts .......................................................................................... 44
Competitive Landscape..........................................45
Pharmaceuticals Sector ................................................................................................ 45
Recent Pharmaceutical Industry Developments............................................................ 45
Company Profiles....................................................47
Indigenous Companies................. 47
Chalhoub Pharmaceuticals (CHAPHA)........................................................................ 47
Alfa Laboratories.................... 48
Algorithm................................ 49
Codipha .................................. 50
Multinational Companies................................................................................................... 51
Pfizer ...................................... 51
Novartis .................................. 52
Merck & Co ............................ 54
Johnson & Johnson................. 56
Sanofi-Aventis......................... 58
GlaxoSmithKline (GSK)................................................................................................ 60
Abbott Laboratories................ 62
Country Snapshot: Lebanon Demographic Data........................................................................................64
Section 1: Population.............. 64
Table: Demographic Indicators, 2005-2030................................................................. 64
Section 2: Education And Healthcare........................................................................... 65
Table: Education, 2002-2005 ....................................................................................... 65
Table: Vital Statistics, 2005-2030................................................................................. 65
Methodology ....................................................66
How We Generate Our Pharmaceutical Industry Forecasts .............................................. 66
Pharmaceutical Business Environment Ratings Methodology ........................................... 67
Ratings Overview.................... 67
Table: Pharmaceutical Business Environment Indicators ............................................ 68
Weighting................................ 69
Table: Weighting Of Components................................................................................. 69
Sources ........................................ 69
Forecast Tables .......................................................70